Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Diabetics Taking Lipitor Show Major Decreases in Heart Attacks, Strokes: ADA Meeting
June 21, 2004
- WEBSITE NEWS
June 21, 2004
- Genes to Predict Paclitaxel Effects Discoverd
June 21, 2004
- Wholesalers May Tie Up with Non-wholesalers: Mr Kimura of CR&C
June 21, 2004
- Uracil + Tegafur Improve Postoperative Survival in Rectal Cancer Patients: ASCO
June 21, 2004
- BUSINESS NEWS IN BRIEF -1-
June 21, 2004
- Tokushukai Group Plans Clinical Trials via Its Network
June 21, 2004
- BUSINESS NEWS IN BRIEF -2-
June 21, 2004
- Large-scale Study Started on Antihypertensive Combination Therapy: Jikei Univ. Group
June 21, 2004
- 5 NCEs Including Octreotide to Be Included in NHI List
June 21, 2004
- Large-Scale Study on Mosapride in Functional Dyspepsia Starts
June 21, 2004
- Chuikyo Members Call For Revision of Drug Pricing Rules
June 21, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
June 21, 2004
- Korosho Holds Hearings on Progress of Action Plan
June 21, 2004
- MEDICAL DEVICE NEWS IN BRIEF
June 21, 2004
- White Paper on Manufacturing Urges International Competitiveness
June 21, 2004
- DIAGNOSTIC NEWS IN BRIEF
June 21, 2004
- REGULATORY NEWS IN BRIEF
June 21, 2004
- Iryo Proverbs Reveal Japanese Spirit (20)
June 21, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
June 21, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…